The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
and so in 2011 with the advent of amyloid imaging you know pittsburgh compound was the first thing that came out that allowed us to see that although its half-life is so terribly short that it really is not clinically um useful because it has to be made and used within minutes um but you know that really allowed us to redefine what alzheimer's is so that we could see this amyloid building up in patients before they started to have symptoms
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
in 2011 with the advent of amyloid imaging you know pittsburgh compound was the first thing that came out that allowed us to see that although its half-life is so terribly short that it really is not clinically um useful because it has to be made and used within minutes — but you know that really allowed us to redefine what alzheimer's is so that we could see this amyloid building up in patients before they started to have symptoms